Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity.

Frontiers in immunology·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.

medRxiv : the preprint server for health sciences·2026
Same author

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same author

Evaluating the accuracy and reliability of telephone-derived Clinical Dementia Rating scores: A comparative analysis with in-person assessments.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The Prodromal Synucleinopathy Rating Scale: An Assessment in Patients With REM Sleep Behavior Disorder.

Neurology·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Kellen K Petersen1, Marta Milà-Alomà2,3, Duygu Tosun2,3

  • 1Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Plasma %p-tau217 clocks can accurately estimate Alzheimer's disease (AD) progression and predict symptom onset. These blood-based tools offer a practical approach for understanding AD timing and potential biological staging.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Biomarkers
  • Alzheimer's Disease Research

Background:

  • Blood biomarkers offer a less invasive alternative to CSF or imaging for tracking Alzheimer's disease (AD).
  • Developing a

Purpose of the Study:

  • To develop and validate plasma %p-tau217 clocks for estimating age at Alzheimer's disease (AD) positivity.
  • To assess the utility of these clocks in predicting symptom onset.

Main Methods:

  • Longitudinal plasma %p-tau217 measurements from Knight ADRC and ADNI cohorts were analyzed.
  • Plasma clocks were constructed by modeling the rate of change in %p-tau217, setting positivity (4.06%) as time zero.
  • The estimated age at positivity was correlated with actual age at conversion and used to predict symptom onset.

Main Results:

  • Two independently developed plasma %p-tau217 clocks showed high consistency and strong correlation with actual age at conversion.
  • The clocks accurately estimated the age at %p-tau217 positivity across both cohorts.
  • Estimated age at positivity predicted symptom onset in both Knight ADRC and ADNI cohorts.

Conclusions:

  • Independently developed plasma %p-tau217 clocks are reliable and consistent across cohorts.
  • These clocks show strong correlation with actual time measures and predict symptom onset.
  • Plasma %p-tau217 clocks show promise for predicting AD symptom onset and enabling biological staging.